Physician profile
Tiffany Ogden
NPI 1871958009
$7,054.07
in general payments reported to CMS, 2019-2025
20 companies · $3,140 in 2025
The $3,140 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $334 · 2022: $1,100 · 2023: $184 · 2024: $2,296 · 2025: $3,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,287 · Travel and Lodging: $2,234 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,287.05 |
| Travel and Lodging | $2,233.58 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,606.35 | 2024-2025 | Synchromedii, Intellis Adaptivestim, Inceptiv |
| Nalu Medical, INC. | $1,407.67 | 2022-2024 | Nalu Neurostimulation System |
| Forte Bio-Pharma LLC | $529.14 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $416.90 | 2021-2025 | Relistor |
| Saluda Medical Americas, INC. | $231.99 | 2025 | Evoke |
| Collegium Pharmaceutical, INC. | $190.23 | 2021-2025 | Belbuca, Xtampza |
| Scilex Pharmaceuticals INC. | $160.90 | 2021-2025 | Ztlido |
| Abbott Laboratories | $90.20 | 2021-2022 | |
| Grt US Holding, INC. | $79.50 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $75.63 | 2024-2025 | |
| Biodelivery Sciences International, INC. | $48.09 | 2021 | |
| Spr Therapeutics, INC | $36.91 | 2025 | Sprint Pns System |
| Pfizer INC. | $32.98 | 2025 | |
| Bioventus LLC | $30.23 | 2021-2022 | |
| Ibsa Pharma INC. | $27.77 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $25.00 | 2025 | Zilretta, Iovera |
| Tonix Medicines, INC. | $19.89 | 2025 | Tonmya |
| Pacira Therapeutics, INC. | $18.77 | 2021 | |
| Almatica Pharma LLC | $13.87 | 2021 | |
| Merck Sharp & Dohme LLC | $12.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Ogden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.